Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.
Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply. These programs are conducted through Vegenics Ltd, a wholly-owned subsidiary of Circadian.

Media Releases

Latest Company News


Feb 2011 11:30 AM
Circadian Technologies enters ..
11 Feb 2011 – Circadian Technologies Limited (ASX:CIR), CEO, Robert Klupacs, explains what the deal means, reports on its successful patent extensions and progress with its diagnostic test being developed with Healthscope.

Contact Information